AR and prostate cancer: Additionally, the same research group demonstrated in a cross-sectional case-control study that androgen receptor blockade, or the inhibition of testosterone production by surgical and/or medical castration of men with prostate cancer, downregulated the platelet TxA2 receptor density, and also reduced platelet aggregation [185].